Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042808 | 0.84 | AGBL2 (0.42) | L3MBTL1TDP1KMT2AGAAPKM | |
| SCHEMBL30328484 | 0.84 | AGBL2 (0.42) | L3MBTL1TDP1KMT2AGAAPKM | |
| SCHEMBL6490655 | 0.80 | L3MBTL1 (0.40) | L3MBTL1TDP1KMT2AGAAPKM | |
| SCHEMBL12415416 | 0.79 | TRPM8 (0.34) | L3MBTL1TDP1KMT2AGAAPKM | |
| SCHEMBL16728654 | 0.78 | PLAU (0.34) | L3MBTL1TDP1KMT2AGAAPKM | |
| SCHEMBL3935059 | 0.77 | TDP1 (0.66) | L3MBTL1TDP1KMT2AGAAPOLB | |
| SCHEMBL6501465 | 0.75 | ALDH1A1 (0.38) | L3MBTL1TDP1KMT2AGAAPKM | |
| SCHEMBL9290492 | 0.75 | TDP1 (0.58) | L3MBTL1TDP1KMT2AGAAPOLB | |
| SCHEMBL30861677 | 0.75 | TDP1 (0.58) | L3MBTL1TDP1KMT2AGAAPOLB | |
| SCHEMBL30861680 | 0.75 | TDP1 (0.58) | L3MBTL1TDP1KMT2AGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344450-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CHAKRAVARTY PRASUN K | 2011-07-14 | — | — | US | disclosed |
| WO-2010036589-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172236-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | L3MBTL1 4377/4885TDP1 3914/4885KMT2A 2427/4885 |
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | L3MBTL1 790/4885TDP1 3080/4885KMT2A 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.